Article PDF
References
Pharmaceutical Research Manufacturer's Association (PhRMA), 1997.
Persidis, A. 1997. Nature Biotechnol. 15:1409–1411.
Such antigens are mostly peptides, but they can also be glycopeptides, lipopeptides, or other types of nonpeptide molecule.
Vose, B.M. and Bonnard, G.D. 1982. Nature 296:359.
Murphy, G. et al. 1996. Prostate 29:371–380.
Kawakami, Y. et al. 1995. J. Immunol. 154:3961–3968.
Mayordomo, J.I. et al. 1995. Nat. Meet. 1:1297–1302.
Vajda, S. and DeLisi, C. 1990. Biopolymers 29:1755.
Skipper, J.C.A. et al. 1996. J. Exp. Med. 183:527–534.
Meadows L. et al. 1997. Immunity 6:273–281.
van der Bruggen, P. et al. 1991. Science 254:1643–1647.
Henderson, R.A. et al. 1993. Proc. Natl. Acad. Sci. USA 90:10275–10279.
Melief, C. et al. 1988. Ann. NY Acad. Sci. 532:280–291.
McCormack, A.L. et al. 1997. Anal. Chem. 69:767–776.
Evers, P. 1996. Immunoheraphy:Current status and markets. Financial Times Management Reports.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Persidis, A. Functional antigenics. Nat Biotechnol 16, 305–307 (1998). https://doi.org/10.1038/nbt0398-305
Issue Date:
DOI: https://doi.org/10.1038/nbt0398-305
This article is cited by
-
High-throughput screening
Nature Biotechnology (1998)